BioNTech develops immunotherapies for cancer and infectious diseases and sells the COVID-19 vaccine Comirnaty. BNTX reports earnings on Tue, Nov 3, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (4 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in BNTX, 100% of them bullish and 0% bearish. In the past 30 days there were 2 dark pool prints.
Prices, price targets and earnings estimates for BNTX are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BNTX is in one of them and how their past BNTX trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About BioNTech SE
BioNTech is a biotechnology company based in Mainz, Germany, that develops medicines based on the immune system. Its main focus is cancer, with further work on vaccines and therapies for infectious diseases, using messenger RNA and protein-based technologies. Its marketed product is Comirnaty, a COVID-19 vaccine sold through partners such as Pfizer and Fosun Pharma in many countries. Its customers are mainly public health authorities and healthcare systems that buy vaccines. Most of its other products are still being tested in clinical trials.
